Condition 1: Melasma. Condition 2: melasma.
Conditions
Interventions
Intervention 1: In this study, for one side of the patient, topical hydroquinone 2% is used at night. Intervention 2: On the other side, the tranexamic acid injection is used by the panel physician, w
it is used by the physician in an interdermal setting at 1 cm intervals in place of melasma. 100 ml insulin is used to inject Nidal. After the local injection, the ice cream compressor will also be us
then patients will follow a monthly follow up for 3 months.
Treatment - Drugs
In this study, for one side of the patient, topical hydroquinone 2% is used at night.
On the other side, the tranexamic acid injection is used by the panel physician, with each side being randomly selected in each patient . During this study, patients will be evaluated for the incidenc
Sponsors
Deputy of Research and Technology of Shiraz University of Medical Sciences
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Inclusion criteria: All patients with melasma Exclusion criteria: Patients treated with steroids; Hydroquinone; Tretinoin; Azaleacic Acid and Kojic Acid; or pregnant; will be excluded. In addition, patients who have taken OCP over the past 12 months and who are taking light-sensitive drugs such as tetracycline; spironolactone; phenytoin and carbamazepine; or coagulation disorders and taking anticoagulant drugs will also be excluded.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Melasma and Melanin Density in Skin. Timepoint: Each 1 month. Method of measurement: Analysis with Dermacath. | — |
Secondary
| Measure | Time frame |
|---|---|
| The Subjective Patient Satisfaction. Timepoint: After 3 month. Method of measurement: By VAS system. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr.Nasrin Saki
Shiraz University of Medical Sciences
Outcome results
None listed